PMLiVE | Pharmaceutical industry news, articles, jobs, reports, …
WEBOptimizing Patient Recruitment & Retention in Influenza Studies. Aug 16, 2024 Webinars. With the flu season rapidly approaching, there is a surge in influenza and vaccine-related studies. These studies often face the significant challenge of a very short recruitment window, which necessitates thorough preparation and strategic planning during ...
Pfizer’s Paxlovid given FDA permission to be prescribed by US ...
WEBJul 7, 2022 · The US Food and Drug Administration (FDA) has revised the Emergency Use Authorisation (EUA) for Paxlovid (nirmatrelvir and ritonavir), authorising pharmacists to prescribe the drug to eligible patients. Under the revision, state-licensed pharmacists will be able to prescribe the drug to patients testing positive for COVID-19, on the condition ...
Moderna shares positive late-stage results for COVID-19/flu …
WEBJun 11, 2024 · Moderna has shared positive late-stage results for its investigational combination vaccine against influenza and COVID-19. The ongoing phase 3 trial has been evaluating the candidate, mRNA-1083, in two age-group cohorts of …
Sanofi/Regeneron’s Dupixent receives FDA approval for …
WEB5 days ago · Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) as an add-on maintenance treatment for adolescents with chronic rhinosinusitis with nasal polyps (CRSwNP). The regulator’s decision, which expands its previous approval of the drug in CRSwNP patients aged 18 years and older ...
PME - Articles - Pharmaceutical Market Europe
WEBNews - July/Aug 2024. Roche and Ascidian agree to $1.8bn neurological disease partnership. 15 July 2024 News & Columns. Read More. Dermatology news - July/Aug 2024. UCB’s Bimzelx approved by MHRA for hidradenitis suppurativa. 15 July 2024 News & Columns. Read More. DARWIN'S MEDICINE - Bayer's octopus move.
Moderna’s COVID-19/flu combination vaccine shows promise in
WEBOct 5, 2023 · Moderna has announced positive results from a phase 1/2 trial of its investigational mRNA combination vaccine against influenza and COVID-19. The combined vaccine approach has the potential to alleviate the impact of both flu and COVID-19 while offering a combined administration, potentially simplifying immunisation practices and leading to higher vaccine uptake.
PME - Home
WEBHow AI and digital innovations can help agencies and pharma support HCPs in the fight against COVID-19 - PME Supplement August 2020. As the realities of COVID-19 hit and lockdown restrictions came into force around the world, agencies and pharma suddenly found themselves embracing AI and digital innovations at an accelerated rate.
Pfizer and BioNTech share positive results for Omicron-adapted …
WEBJun 27, 2022 · Pfizer and BioNTech have shared positive results from a phase 2/3 trial of two Omicron-adapted COVID-19 vaccine candidates. The data shows that a booster dose of both Omicron-adapted vaccines gave a considerably higher immune response against Omicron BA.1, compared to Pfizer/BioNTech’s current COVID-19 vaccine.
Bristol Myers Squibb’s Krazati granted FDA accelerated approval in ...
WEBJun 24, 2024 · Taken orally twice daily, Krazati is a small-molecule inhibitor of KRASG12C and is already approved in the US to treat specific cases of non-small cell cancer (NSCLC). The FDA’s latest decision was supported by positive results from cohorts of the phase 1/2 KRYSTAL-1 study, in which Krazati plus cetuximab demonstrated a confirmed objective ...
Johnson & Johnson's IL-23 inhibitor Tremfya granted FDA …
WEBSep 12, 2024 · Johnson & Johnson’s (J&J) dual-acting IL-23 inhibitor Tremfya (guselkumab) has been approved by the US Food and Drug Administration (FDA) to treat adults with moderately to severely active ulcerative colitis (UC). Estimated to affect more than one million people in the US, UC is a type of inflammatory bowel disease (IBD) that causes ...